NHS access rules leave secondary breast cancer patient outside Enhertu eligibility
A woman living with secondary breast cancer has been told she cannot receive Enhertu through the NHS because she is already on her third round of chemotherapy. The drug is available within NHS England, but only for people who have had one or two previous lines of chemotherapy, a rule that now places her beyond the current treatment window despite the seriousness of her disease.
Laura Stanford, a mother-of-five from Minster on the Isle of Sheppey in Kent, has incurable breast cancer that has spread to her liver and bones. She recently became a grandmother and is preparing for her daughter’s wedding in December. Her account places a human face on a hard boundary in cancer care: once a patient crosses a treatment threshold, access can disappear even when the next option may offer a better chance of prolonging life.
Her situation is defined by progression, not preference.
Stanford was diagnosed with primary breast cancer in 2022. The disease has since advanced, and she is now receiving chemotherapy for metastatic spread. She said she cannot afford to pay privately for Enhertu, leaving the family to search for a way to raise money if they want to pursue the drug outside the NHS. In practical terms, the issue is not whether the medicine exists, but whether a patient who has already needed multiple rounds of cytotoxic therapy can still fit within the eligibility framework attached to it.
Why Enhertu sits outside the current chemotherapy sequence
Enhertu is reserved in NHS England for patients with secondary breast cancer who have had one or two prior lines of chemotherapy. The restriction reflects the evidence base used by the National Institute for Health and Care Excellence and NHS decision-makers, who have linked the treatment to a defined patient group. In this case, the selection rule is narrow because it follows the trial population rather than the much messier reality of metastatic cancer progression, where patients do not always respond on schedule or remain stable long enough to stay inside a preferred treatment sequence.
That creates an uncomfortable clinical mismatch. A person who progresses more quickly than expected may need to move to a third regimen before the next targeted option becomes available, even if the later-line disease still appears biologically suitable for it. For patients and families, the timing of disease escalation can determine whether a drug is accessible at all, and that can feel arbitrary when the underlying illness is already incurable.
Stanford said that if she cannot have Enhertu, she believes she has only two or three options left, and that those remaining treatments are less likely to work for her. She described the situation as devastating and unfair, arguing that women have been left without entitlement to a drug simply because their cancer progressed far enough to require a third line of chemotherapy. Her language captures the central tension in metastatic oncology: the most effective therapy on paper may become inaccessible once a patient has already moved beyond the line where it was studied.
Family pressure, private cost, and the limits of evidence-based access
Her daughter Faith said the situation is hard and deeply upsetting, adding that the family feels under pressure to help keep her mother alive for longer. That kind of strain is common when publicly funded cancer treatment intersects with private cost. For families, the therapeutic gap becomes financial as well as clinical, and the burden can shift abruptly from the oncology clinic to fundraising, appeals, and the uncertainty of whether enough money can be raised in time.
NHS England said it recognises how important access to Enhertu is for people living with secondary breast cancer and their families. The service also said its guidance is based on the latest clinical evidence to ensure patients receive the best and safest care. Eligibility criteria for the therapy were translated directly from trial evidence and the patient group assessed by NICE, which found Enhertu safe and effective for those who had previously received only one or two courses of chemotherapy.
Those sentences explain the policy logic, but they do not soften the impact at the bedside. Trial-derived criteria are often built to protect patients from unsupported use, overpromise, or toxicity in groups not adequately studied. At the same time, rigid boundaries can exclude people whose disease course has simply been faster or more aggressive than the average trial participant. In metastatic breast cancer, where each line of therapy often carries diminishing benefit, a narrow access rule can convert a promising option into a missed opportunity.
The biological appeal of Enhertu lies in its role as a targeted anticancer treatment for advanced disease after earlier chemotherapy has already failed. In a patient whose cancer has spread to the liver and bones, any drug with a meaningful chance of slowing tumor growth can carry real consequence: more time, more symptom control, and occasionally enough stability to attend family milestones that would otherwise be lost to the disease. Stanford’s hope is rooted in that possibility, not in abstraction.
Her case also exposes a frequent fault line in oncology commissioning. Evidence is usually generated in carefully defined groups, yet real patients arrive with treatment histories that no longer match the neat order of a protocol. Once progression forces another chemotherapy switch, the very sequencing that kept the disease under review can also block access to later targeted therapy. The result is a policy decision that is evidence-based, but still painfully unforgiving for the person living it.
For now, the family is trying to raise money privately. The clinical question is simple and unforgiving: whether a patient who has moved to a third chemotherapy line because of cancer progression should be allowed access to a drug that might extend life, even when the current NHS criteria place her outside eligibility. The answer remains fixed by the present guidance, and that leaves Stanford facing the consequences of a disease that has advanced one step beyond the treatment pathway built around it.